Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL857 | 0.76 | IDO1 (0.39) | LMNAMAPK1TSHRADRA2ACYP2D6 | |
| SCHEMBL710572 | 0.74 | CYP2D6 (0.46) | LMNAMAPK1ALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL16970628 | 0.73 | HCAR2 (0.43) | LMNAALDH1A1KDM4EADRA2AADRA2C | |
| SCHEMBL16970750 | 0.73 | HCAR2 (0.43) | LMNAALDH1A1KDM4EADRA2AADRA2C | |
| SCHEMBL119992 | 0.73 | TSHR (0.44) | LMNAMAPK1TSHRALDH1A1CYP2D6 | |
| SCHEMBL7454768 | 0.73 | TSHR (0.44) | LMNAMAPK1TSHRALDH1A1CYP2D6 | |
| SCHEMBL96935 | 0.73 | HCAR2 (0.43) | LMNAALDH1A1KDM4EADRA2AADRA2C | |
| SCHEMBL2657967 | 0.73 | CYP2D6 (0.34) | LMNAMAPK1TSHRALDH1A1CYP2D6 | |
| SCHEMBL535087 | 0.73 | DPP4 (0.44) | LMNAALDH1A1KDM4EADRA2AADRA2C | |
| SCHEMBL131810 | 0.73 | CES2 (0.41) | LMNAMAPK1TSHRALDH1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018134412-A1 | ANTIMICROBIAL COMPOUNDS AND USES THEREOF | BIOSYNTH AG (CH) | 2018-07-26 | — | — | WO | claimed |
| US-20200289662-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2020-09-17 | — | — | US | disclosed |
| US-10583197-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2020-03-10 | — | — | US | disclosed |
| EP-3610889-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LegoChem Biosciences, Inc. (KR) | 2020-02-19 | — | — | EP | disclosed |
| EP-2707031-B1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHOD FOR PREPARING THE SAME | LEGOCHEM BIOSCIENCES INC (KR) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018134412-A1 | ANTIMICROBIAL COMPOUNDS AND USES THEREOF | BIOSYNTH AG (CH) | 2018-07-26 | — | — | WO | disclosed |
| US-20180021451-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2018-01-25 | — | — | US | disclosed |
| US-9669107-B2 | Antibody-active agent conjugates and methods of use | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-06 | — | — | US | disclosed |
| US-20160213786-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LEGOCHEM BIOSCIENCES, INC. (KR) | 2016-07-28 | — | — | US | disclosed |
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | LIGACHEM BIOSCIENCES INC. (KR) | 2015-04-16 | — | — | US | disclosed |
| EP-1484191-A1 | REWRITABLE OPTICAL INFORMATION RECORDING MEDIUM AND RECORDING/REPRODUCING METHOD, RECORDING/REPRODUCING DEVICE | Sony Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
| US-20030194646-A1 | Mono-, di-, and triazaporphyrin compounds optionally in the form of a metal or metalloid complex | MITSUI CHEMICALS, INC. (JP) | 2003-10-16 | — | — | US | disclosed |
| US-6627288-B1 | Optical recording medium and porphycene compound | MITSUI CHEMICALS, INC. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | MITSUI CHEMICALS, INC. (JP) | 2003-05-15 | — | — | US | disclosed |
| EP-1262966-A2 | Optical recording medium and novel azaporphyrin compound | Mitsui Chemicals, Inc. (JP) | 2002-12-04 | — | — | EP | disclosed |
| EP-1247655-A1 | OPTICAL RECORDING MEDIUM AND NOVEL AZAPORPHYRIN COMPOUNDS | Mitsui Chemicals, Inc. (JP) | 2002-10-09 | — | — | EP | disclosed |
| EP-1245571-A1 | BENZBISAZOLE COMPOUND AND OPTICAL RECORDING MEDIUM CONTAINING THE COMPOUND | Mitsui Chemicals, Inc. (JP) | 2002-10-02 | — | — | EP | disclosed |
| EP-1180765-A1 | Optical recording medium and porphycene compound | Mitsui Chemicals, Inc. (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-0543662-B1 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | SANKYO CO (JP) | 1996-09-18 | — | — | EP | disclosed |
| EP-0543662-A2 | Aromatic amino-alcohol derivatives having anti-diabetic and anti-obesity properties, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213786-A1 | PROTEIN-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FNTA, FCGRT, GGT1 | LMNA 2831/4885MAPK1 4198/4885TSHR 3900/4885 |
| US-20150105541-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | LMNA 3728/4885MAPK1 4402/4885TSHR 3065/4885 |
| US-20200289662-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | LMNA 3728/4885MAPK1 4402/4885TSHR 3065/4885 |
| US-10583197-B2 | Antibody-active agent conjugates and methods of use | FNTA, FCGRT, CD47 | LMNA 3858/4885MAPK1 4365/4885TSHR 3204/4885 |
| US-20030091931-A1 | Benzbisazole compound and optical recording medium containing the compound | DAO, CACNA1I, KCNB2 | LMNA 816/4885MAPK1 711/4885TSHR 3514/4885 |
| US-20180021451-A1 | ANTIBODY-ACTIVE AGENT CONJUGATES AND METHODS OF USE | FCGRT, CD47, FNTA | LMNA 3728/4885MAPK1 4402/4885TSHR 3065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.